Frazier Life Sciences Management
Latest statistics and disclosures from Frazier Life Sciences Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MIRM, NAMS, PHAT, KRYS, Mbx Biosciences, and represent 39.59% of Frazier Life Sciences Management's stock portfolio.
- Added to shares of these 10 stocks: Mbx Biosciences (+$156M), ASND (+$20M), ALKS (+$16M), Oruka Therapeutics (+$12M), RARE (+$12M), LXEO (+$11M), NAMS (+$10M), DAWN (+$9.6M), ERAS (+$8.7M), AGIO (+$7.6M).
- Started 8 new stock positions in Oruka Therapeutics, LXEO, DAWN, ASND, PIRS, NUVB, ALKS, Mbx Biosciences.
- Reduced shares in these 9 stocks: EWTX (-$24M), PCVX (-$18M), CERE (-$16M), APLT (-$11M), PEPG (-$6.8M), ANTX, TYRA, RCKT, MGX.
- Sold out of its positions in ANTX, APLT, CERE, MGX.
- Frazier Life Sciences Management was a net buyer of stock by $203M.
- Frazier Life Sciences Management has $2.5B in assets under management (AUM), dropping by 16.72%.
- Central Index Key (CIK): 0001892134
Tip: Access up to 7 years of quarterly data
Positions held by Frazier Life Sciences Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Frazier Life Sciences Management
Frazier Life Sciences Management holds 53 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals (MIRM) | 10.3 | $256M | 6.6M | 39.00 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 8.6 | $213M | +5% | 13M | 16.60 |
|
| Phathom Pharmaceuticals (PHAT) | 7.3 | $183M | 10M | 18.08 |
|
|
| Krystal Biotech (KRYS) | 7.2 | $180M | 989k | 182.03 |
|
|
| Mbx Biosciences | 6.2 | $156M | NEW | 6.0M | 25.98 |
|
| Rhythm Pharmaceuticals (RYTM) | 5.1 | $127M | 2.4M | 52.39 |
|
|
| Vaxcyte (PCVX) | 4.0 | $101M | -15% | 879k | 114.27 |
|
| Verona Pharma Sponsored Ads (VRNA) | 3.9 | $97M | +2% | 3.4M | 28.77 |
|
| Bridgebio Pharma (BBIO) | 3.8 | $96M | +3% | 3.8M | 25.46 |
|
| Disc Medicine (IRON) | 3.5 | $86M | 1.8M | 49.14 |
|
|
| Arcutis Biotherapeutics (ARQT) | 3.3 | $82M | 8.8M | 9.30 |
|
|
| Edgewise Therapeutics (EWTX) | 3.0 | $76M | -24% | 2.8M | 26.69 |
|
| Anaptysbio Inc Common (ANAB) | 3.0 | $74M | +2% | 2.2M | 33.50 |
|
| Erasca (ERAS) | 2.1 | $53M | +19% | 19M | 2.73 |
|
| Tarsus Pharmaceuticals (TARS) | 2.1 | $52M | 1.6M | 32.89 |
|
|
| Agios Pharmaceuticals (AGIO) | 1.9 | $46M | +19% | 1.0M | 44.43 |
|
| Revolution Medicines (RVMD) | 1.8 | $45M | 998k | 45.35 |
|
|
| Soleno Therapeutics (SLNO) | 1.8 | $44M | 876k | 50.49 |
|
|
| Kalvista Pharmaceuticals (KALV) | 1.7 | $43M | 3.7M | 11.58 |
|
|
| Oric Pharmaceuticals (ORIC) | 1.7 | $43M | 4.1M | 10.25 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 1.4 | $35M | +49% | 634k | 55.55 |
|
| Savara (SVRA) | 1.4 | $35M | 8.2M | 4.24 |
|
|
| Cg Oncology (CGON) | 1.2 | $29M | 770k | 37.73 |
|
|
| Rocket Pharmaceuticals (RCKT) | 1.1 | $27M | -4% | 1.5M | 18.47 |
|
| Trevi Therapeutics (TRVI) | 1.0 | $25M | 7.4M | 3.34 |
|
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.8 | $21M | +15% | 5.1M | 4.11 |
|
| Silence Therapeutics Ads (SLN) | 0.8 | $21M | 1.1M | 18.18 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.8 | $20M | NEW | 133k | 149.31 |
|
| Hillevax (HLVX) | 0.7 | $19M | 11M | 1.76 |
|
|
| Merus N V (MRUS) | 0.7 | $19M | 373k | 49.96 |
|
|
| Tyra Biosciences (TYRA) | 0.7 | $17M | -12% | 731k | 23.51 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.7 | $17M | 4.6M | 3.63 |
|
|
| Alkermes SHS (ALKS) | 0.6 | $16M | NEW | 576k | 27.99 |
|
| Immatics SHS (IMTX) | 0.6 | $16M | +17% | 1.4M | 11.41 |
|
| Oruka Therapeutics | 0.5 | $12M | NEW | 477k | 24.51 |
|
| Lexeo Therapeutics (LXEO) | 0.5 | $11M | NEW | 1.3M | 9.04 |
|
| Design Therapeutics (DSGN) | 0.4 | $10M | +58% | 1.9M | 5.38 |
|
| Cogent Biosciences (COGT) | 0.4 | $10M | 937k | 10.80 |
|
|
| Macrogenics (MGNX) | 0.4 | $9.9M | 3.0M | 3.29 |
|
|
| Day One Biopharmaceuticals I (DAWN) | 0.4 | $9.6M | NEW | 690k | 13.93 |
|
| Allogene Therapeutics (ALLO) | 0.3 | $8.0M | 2.9M | 2.80 |
|
|
| Puma Biotechnology (PBYI) | 0.3 | $7.8M | 3.1M | 2.55 |
|
|
| Adverum Biotechnologies Com New (ADVM) | 0.3 | $7.5M | 1.1M | 7.02 |
|
|
| 89bio (ETNB) | 0.3 | $7.4M | 1.0M | 7.40 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 0.3 | $7.2M | 470k | 15.38 |
|
|
| Arvinas Ord (ARVN) | 0.3 | $7.0M | 285k | 24.63 |
|
|
| Pepgen (PEPG) | 0.2 | $6.0M | -53% | 703k | 8.55 |
|
| Elevation Oncology (ELEV) | 0.1 | $3.6M | +102% | 6.0M | 0.60 |
|
| Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.1 | $3.5M | 500k | 7.00 |
|
|
| Immunocore Hldgs Ads (IMCR) | 0.1 | $3.4M | 109k | 31.13 |
|
|
| Nuvation Bio Com Cl A (NUVB) | 0.1 | $2.8M | NEW | 1.2M | 2.29 |
|
| Aclaris Therapeutics (ACRS) | 0.0 | $304k | 264k | 1.15 |
|
|
| Pieris Pharmaceuticals Com New (PIRS) | 0.0 | $267k | NEW | 16k | 16.74 |
|
Past Filings by Frazier Life Sciences Management
SEC 13F filings are viewable for Frazier Life Sciences Management going back to 2022
- Frazier Life Sciences Management 2024 Q3 filed Nov. 15, 2024
- Frazier Life Sciences Management 2024 Q2 filed Aug. 15, 2024
- Frazier Life Sciences Management 2024 Q1 filed May 15, 2024
- Frazier Life Sciences Management 2023 Q4 filed Feb. 14, 2024
- Frazier Life Sciences Management 2023 Q3 filed Nov. 14, 2023
- Frazier Life Sciences Management 2023 Q2 filed Aug. 14, 2023
- Frazier Life Sciences Management 2023 Q1 filed May 15, 2023
- Frazier Life Sciences Management 2022 Q4 restated filed Feb. 7, 2023
- Frazier Life Sciences Management 2022 Q4 filed Feb. 3, 2023
- Frazier Life Sciences Management 2022 Q3 filed Nov. 14, 2022
- Frazier Life Sciences Management 2022 Q2 filed Aug. 10, 2022
- Frazier Life Sciences Management 2022 Q1 filed May 16, 2022